What does ixX pharma do?

ixX pharma is registered with the CBE as active in: Groothandel in farmaceutische producten. Public Limited, started on 26 April 2005, 1 establishment.

What is the address of ixX pharma?

The registered office of ixX pharma is located at Borsbeeksebrug 34, 2600 Antwerpen.

Is ixX pharma still active?

Yes. According to the CBE (31 October 2026) ixX pharma is active, legal situation “Normale toestand”, started on 26 April 2005.

Is ixX pharma registered on Peppol?

Yes, ixX pharma is registered on the Peppol network with ID 0208:0873490740.

What is the enterprise number of ixX pharma?

The enterprise number of ixX pharma is BE0873490740.

When was ixX pharma founded?

ixX pharma was founded on 26 April 2005.

Who are the directors of ixX pharma?

According to the 2025 annual accounts, the directors of ixX pharma are: Ponroy Vitarmonyl Benelux BV, Matthieu Mourette.

Is ixX pharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 26 April 2005; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did ixX pharma make in 2025?

ixX pharma posted a profit after taxes of € 1,692,646 in financial year 2025.

What is the revenue of ixX pharma?

In its most recent annual accounts (2025), ixX pharma reported revenue of € 11,631,876.

How much does an employee at ixX pharma earn?

The average wage cost per full-time employee at ixX pharma was € 95,400 in 2025: staff costs of € 2.5 million for 26.3 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does ixX pharma have?

According to the 2025 annual accounts, ixX pharma has 26.3 full-time equivalents (FTE).

Does ixX pharma have a website?

Yes, ixX pharma has a website at ixx.be.

ixX pharma (Public Limited) - Antwerpen - BE0873490740

Dossier ixX pharma, printed on 31 October 2026 from databakkes.be/en/0873490740/ixx-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Busy address KBO

61 other companies have their registered office at the same address; threshold 10.

Financials

Financial year 2025

ixX pharma from Antwerpen, company number BE0873490740, closed financial year 2025 with a result of € 1.7 million after tax. For that financial year ixX pharma recorded revenue of € 11.6 million and equity of € 6.9 million. Compared with financial year 2024, the result moved from € 1.2 million to € 1.7 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.

What it is worth Growing

€ 6.9 million

▲ 10% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 1.7 million

▲ 40% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 1.3 million

▲ 3% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 1.1 million paid out

62 % of the profit went to the shareholders, mostly to Ponroy Vitarmonyl Benelux BV (100 % of the shares). That is where the money ends up.

People and assets in 2025

Full-time equivalents

26.3

▼ 1.1 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost Staff costs are payroll only. Director pay sits with services and miscellaneous goods: € 3 million in 2025, together with rent, insurance, accountants and other services. The accounts do not split that further.

€ 2.5 million

▼ 2% vs 2024

€ 95,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Debts at end 2025

Bank debt

€ 1 million

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 1.1 million

▼ 51% vs 2024

Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 52 days on average.

Taxes and wages

€ 997,907

▲ 33% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 9,726,325 Revenue 2022: € 9,726,325 First fiscal year in the series	€ 10,436,315 Revenue 2023: € 10,436,315 ▲ 7% vs 2022 (€ 9,726,325) Favourable step	€ 12,768,776 Revenue 2024: € 12,768,776 ▲ 22% vs 2023 (€ 10,436,315) Favourable step	€ 11,631,876 Revenue 2025: € 11,631,876 ▼ 9% vs 2024 (€ 12,768,776) Unfavourable step	▼ 9%
Profit after taxes	€ 392,379 Profit after taxes 2022: € 392,379 First fiscal year in the series	€ 1,010,190 Profit after taxes 2023: € 1,010,190 ▲ 157% vs 2022 (€ 392,379) Favourable step	€ 1,206,625 Profit after taxes 2024: € 1,206,625 ▲ 19% vs 2023 (€ 1,010,190) Favourable step	€ 1,692,646 Profit after taxes 2025: € 1,692,646 ▲ 40% vs 2024 (€ 1,206,625) Favourable step	▲ 40%
Equity	€ 4,829,163 Equity 2022: € 4,829,163 First fiscal year in the series	€ 5,076,852 Equity 2023: € 5,076,852 ▲ 5% vs 2022 (€ 4,829,163) Favourable step	€ 6,283,477 Equity 2024: € 6,283,477 ▲ 24% vs 2023 (€ 5,076,852) Favourable step	€ 6,926,124 Equity 2025: € 6,926,124 ▲ 10% vs 2024 (€ 6,283,477) Favourable step	▲ 10%
Total debts	€ 2,567,604 Total debts 2022: € 2,567,604 First fiscal year in the series	€ 3,665,874 Total debts 2023: € 3,665,874 ▲ 43% vs 2022 (€ 2,567,604) Unfavourable step	€ 4,010,450 Total debts 2024: € 4,010,450 ▲ 9% vs 2023 (€ 3,665,874) Unfavourable step	€ 4,347,912 Total debts 2025: € 4,347,912 ▲ 8% vs 2024 (€ 4,010,450) Unfavourable step	▲ 8%
Cash	€ 838,793 Cash 2022: € 838,793 First fiscal year in the series	€ 1,072,640 Cash 2023: € 1,072,640 ▲ 28% vs 2022 (€ 838,793) Favourable step	€ 1,313,062 Cash 2024: € 1,313,062 ▲ 22% vs 2023 (€ 1,072,640) Favourable step	€ 1,347,465 Cash 2025: € 1,347,465 ▲ 3% vs 2024 (€ 1,313,062) Favourable step	▲ 3%
Land & buildings	€ 635,463 Land & buildings 2022: € 635,463 First fiscal year in the series	€ 574,926 Land & buildings 2023: € 574,926 ▼ 10% vs 2022 (€ 635,463) Unchanged	€ 514,714 Land & buildings 2024: € 514,714 ▼ 10% vs 2023 (€ 574,926) Unchanged	-
Retained profit	€ 4,316,714 Retained profit 2022: € 4,316,714 First fiscal year in the series	€ 4,476,904 Retained profit 2023: € 4,476,904 ▲ 4% vs 2022 (€ 4,316,714) Favourable step	€ 5,683,528 Retained profit 2024: € 5,683,528 ▲ 27% vs 2023 (€ 4,476,904) Favourable step	€ 6,326,175 Retained profit 2025: € 6,326,175 ▲ 11% vs 2024 (€ 5,683,528) Favourable step	▲ 11%
Dividend	€ 1,000,000 Dividend 2022: € 1,000,000 First fiscal year in the series	€ 850,000 Dividend 2023: € 850,000 ▼ 15% vs 2022 (€ 1,000,000) Unchanged	€ 0 Dividend 2024: € 0 ▼ 100% vs 2023 (€ 850,000) Unchanged	€ 1,050,000 Dividend 2025: € 1,050,000 Unchanged (€ 0) Unchanged
Bank debt	€ 1,000,000 Bank debt 2022: € 1,000,000 First fiscal year in the series	€ 1,000,000 Bank debt 2023: € 1,000,000 Unchanged (€ 1,000,000) Unchanged	€ 1,000,000 Bank debt 2024: € 1,000,000 Unchanged (€ 1,000,000) Unchanged	€ 1,000,000 Bank debt 2025: € 1,000,000 Unchanged (€ 1,000,000) Unchanged
Balance sheet total	€ 7,396,767 Balance sheet total 2022: € 7,396,767 First fiscal year in the series	€ 8,742,726 Balance sheet total 2023: € 8,742,726 ▲ 18% vs 2022 (€ 7,396,767) Unchanged	€ 10,293,927 Balance sheet total 2024: € 10,293,927 ▲ 18% vs 2023 (€ 8,742,726) Unchanged	€ 11,274,036 Balance sheet total 2025: € 11,274,036 ▲ 10% vs 2024 (€ 10,293,927) Unchanged	▲ 10%
Employees (FTE)	19 Employees (FTE) 2022: 19 First fiscal year in the series	21.8 Employees (FTE) 2023: 21.8 ▲ 2.8 vs 2022 (19) Unchanged	27.4 Employees (FTE) 2024: 27.4 ▲ 5.6 vs 2023 (21.8) Unchanged	26.3 Employees (FTE) 2025: 26.3 ▼ 1.1 vs 2024 (27.4) Unchanged	▼ 1.1

Key figures of ixX pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to ixX pharma?

What happened at ixX pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 31, 2026 New annual accounts for financial year 2025: profit of € 1.7 million (▲ 40% vs 2024). filed late Source: NBB ↗
2026 Ponroy Vitarmonyl Benelux BV stepped down as director. NBB
2026 Matthieu Mourette stepped down as director. NBB
2021 Ponroy Vitarmonyl Benelux BV became a director. NBB
2021 Matthieu Mourette became a director. NBB
Apr 26, 2005 New establishment in Antwerpen. KBO
Apr 26, 2005 Start of the company according to the CBE. KBO

In short

From € 392,379 profit in 2022 to € 1.7 million profit in 2025.

Paid € 1.6 million in corporate taxes since 2022.

Best year ever: 2025, with € 1.7 million profit.

Paid out € 2.9 million in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Ponroy Vitarmonyl Benelux BV 100%

ixX pharma

Biocyte Benelux 100%

The shares are held by Ponroy Vitarmonyl Benelux BV (100%). It owns 100% of Biocyte Benelux itself.

Directors

According to the 2025 annual accounts

Ponroy Vitarmonyl Benelux BV

Managing director · represented by Nicolas Brodetsky

since 2021 · until 2026

Matthieu Mourette

Director

since 2021 · until 2026

Shareholders

Ponroy Vitarmonyl Benelux BV

100%

Participations

Biocyte Benelux

100%

Establishments

Establishment units

Physical locations of this company

Registered office

Borsbeeksebrug 34

2600 Antwerpen

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 61 companies are registered at this address.

All companies at this address →

Athena

PIZZA BELGIUM

€ 45.8 million revenue · 2025

MABEMI

€ -5,762 gross margin · 2022

C & C LASER

€ -50,670 gross margin · 2025

Linde Gas Belgium

€ 13.1 million revenue · 2025

+56 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS ixx.be

Technologies

AutoptimizeContact Form 7PHPSlickWordPressYoast SEOjQueryreCAPTCHA

Hosting & Email

Email provider

Microsoft 365

Hosting

OVH, FR

Website info

HTTPS Ja

Languages FR, NL

Features

Webshop Blog Contact page

Security

✓ HTTPS

✓ SPF

✓ DMARC

Network

✓ IPv6

Details

Company number

0873.490.740

VAT number

BE 0873.490.740

Registered office

Borsbeeksebrug 34, 2600 Antwerpen

Names & denominations

ixX pharma

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

26 April 2005

Peppol

Active · Active since 30 Jul 2025

Contact

ixx.be

Activities · NACE

Groothandel in farmaceutische producten

Groothandel in farmaceutische en medische artikelen

View on CBE Public ↗ Annual accounts (NBB) ↗

ixX pharma

Warning lights

Financials

What happened to ixX pharma?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Website

Technologies

Hosting & Email

Website info

Features

Security

Network

Details

Frequently asked questions